Skip to main content
Subscribe
Log In
More
Log in via Institution
Log in via OpenAthens
Log in via your Society
Select your society
ESGO
IGCS
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Current issue
Archive
Authors
About
YouTube
Podcasts
Zoom Journal Club
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Current issue
Archive
Authors
About
YouTube
Podcasts
Zoom Journal Club
Subscribe
Log in
More
Log in via Institution
Log in via OpenAthens
Log in via your Society
Select your society
ESGO
IGCS
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Archive
Volume 34, Issue Suppl 1
1222 Bevacizumab in the first-line treatment of ovarian cancer: UK single centre experience
Email alerts
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Rapid Responses
Article
metrics
Alerts
PDF
Poster and E-Posters
06. Ovarian cancer
1222 Bevacizumab in the first-line treatment of ovarian cancer: UK single centre experience
Online download statistics by month:
Online download statistics by month: March 2024 to October 2024
Abstract
Full
Pdf
Mar 2024
93
0
6
Apr 2024
47
0
1
May 2024
37
0
1
Jun 2024
34
0
0
Jul 2024
12
0
0
Aug 2024
24
0
1
Sep 2024
74
0
5
Oct 2024
6
0
0
Total
327
0
14
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in via your Society
Select your society
ESGO
IGCS
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
PDF